China's Shanghai INT Medical Instruments H1 revenue jumps on acquisitions

Shanghai INT Medical Instruments

24/08/2026 14:23

Overview
China medical device maker's H1 revenue rose 29% yr/yr, driven by acquisitions and higher device sales
Profit for the period increased 23% from a year earlier
Basic and diluted EPS fell 5% yr/yr despite higher profit

Outlook
Company did not provide specific financial guidance or outlook for future periods in the press release

Result Drivers
ACQUISITIONS AND MERGERS - Co said revenue growth was mainly driven by acquisitions, merger filling product gaps, and expanded product category matrix
DEVICE SALES GROWTH - Co said higher sales of interventional medical devices contributed to revenue increase
PRODUCT MIX SHIFT - Co said improved gross profit margin was due to product mix changes, with lower proportion of agency business revenue

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 596.1 mln
 
H1 Net Income Attributable
 
RMB 110.3 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Shanghai interest Medical Instruments Co Ltd is HK$33.68, about 1.5% below its August 24 closing price of HK$34.20
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 26 three months ago

Reuters Recommended Reads
Aug 24 - China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growth
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)